WOBURN, Mass. (Aug. 20, 2019) – ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the United States Patent and Trademark Office has issued two additional U.S. patents that are directed to the formulation, methods of use and administration of ROMEG’s proprietary colchicine …
Author Archives: gotcha_admin
ATLANTA, (July 16, 2019) – Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, has announced the license and commercialization agreement with ROMEG Therapeutics, LLC, for the exclusive rights to launch Gloperba – an oral solution for adults suffering from gout – in the United States. Gloperba is a new liquid oral dosage form of colchicine indicated …
30
Jan
Jan
ROMEG has received FDA approval for its product GLOPERBA®. FOR IMMEDIATE RELEASE Contact: Greg Turner, Ball Consulting Group, LLC Phone: 617-243-9950 Email: greg@ballcg.com ROMEG Therapeutics Receives FDA Approval of GLOPERBA® (colchicine) for Prophylaxis of Adult Gout Flares GLOPERBA® is the First FDA-approved Liquid Formulation for Prophylaxis of Gout Flares and Designed to Meet Dose …
12
Dec
Dec
ROMEG has received its patent allowance.
06
Mar
Mar
ROMEG has been issued a patent.